OncoMatch/Clinical Trials/NCT05552222

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Official title: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy

Is NCT05552222 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments for multiple myeloma.

Phase 3RecruitingJanssen Research & Development, LLCNCT05552222Data as of Oct 2026Location: International · 25 countries

Treatment: Teclistamab · Daratumumab · Lenalidomide · Dexamethasone · Talquetamab — The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

TeclistamabDaratumumabTalquetamab

Endocrine / hormonal

Lenalidomide

Other

Dexamethasone

Cancer type

Multiple Myeloma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any therapy for multiple myeloma or smoldering myeloma

Exception: short course of corticosteroids (not to exceed total of 160 mg dexamethasone or equivalent)

Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent)

Cannot have received: systemic corticosteroids

received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization

Cannot have received: plasmapheresis

Had plasmapheresis within 28 days of randomization

Structured fields extracted by AI. May contain errors — verify against the official protocol.

What participants and caregivers reported

2 accounts found in public discussions of this study. These are individual experiences, not study results.

Making the decision · Not knowing the assignment · Visit schedule · Side effects

Considering joining · United Kingdom — clinic not named · January 2026 · Deciding between the trial and standard treatment

A newly diagnosed patient wrote about choosing between this trial and an established treatment regimen. They weighed the three-way randomization, how much was still unknown about the newer drug combinations, what side effects might follow, and whether the trial could be delivered at the clinic they already attended.

One person's experience · May be specific to this site · Does not confirm they joined

Read the original ↗Macmillan Online Community

Why this was linked to NCT05552222

The patient names MajesTEC-7 and lists its exact treatment options for newly diagnosed myeloma.

Not knowing the assignment · Communication with the team · Making the decision · Side effects

Caregiver · Türkiye — site not named · October 2024 · Family member expected to join; enrollment not confirmed

A caregiver whose mother was expected to join wrote that the family did not know which of the three treatment groups she would be assigned to, and felt they had not been given enough information by her doctor. They asked other patients what to expect and how to prepare.

This was posted more than 18 months ago. Study requirements and visit schedules change — confirm anything practical with the study team.

One person's experience · May be specific to this site · Does not confirm they joined · The study may have changed since

Read the original ↗Reddit — r/multiplemyeloma

Why this was linked to NCT05552222

The post names MajesTEC-7 and all three of its treatment groups, and a reply links to this study's registry record.

These are paraphrased from public posts and articles, each linked to its source. We check that a post is about this study, but we cannot verify what it describes. Nothing here is medical advice, and none of it should be read as evidence that a treatment works.

US trial sites

Banner MD Anderson Cancer Center · Gilbert, Arizona
University of Arizona Cancer Center · Tucson, Arizona
UCSF Fresno · Clovis, California
City of Hope Duarte · Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05552222 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Multiple Myeloma trials